Why the study?
Does a multimodality endovascular approach with argatroban relieve venous occlusion and salvage the limb in a patient with phlegmasia cerulea dolens and heparin-induced thrombocytopenia?
Does a multimodality endovascular approach with argatroban relieve venous occlusion and salvage the limb in a patient with phlegmasia cerulea dolens and heparin-induced thrombocytopenia?
A multimodality endovascular approach using argatroban can successfully treat phlegmasia cerulea dolens in patients with heparin-induced thrombocytopenia.
May support argatroban-based endovascular salvage in HIT-associated phlegmasia cerulea dolens; hypothesis-generating and requires prospective validation.
Phlegmasia cerulea dolens is a limb-threatening form of deep venous thrombosis and should be treated aggressively. The authors report a patient who presented with iliocaval and femoral deep venous thrombosis and posed an additional therapeutic challenge based on a recent history of heparin-induced thrombocytopenia. Catheter-directed pharmacologic thrombolysis and balloon venoplasty were applied in treatment. The direct thrombin inhibitor argatroban was used in place of heparin for concurrent anticoagulation. This multimodality endovascular approach (chemical and mechanical interventions) was successful in relieving the venous occlusion and salvaging the limb, while maintaining appropriate treatment for heparin-induced thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: